Abstract 486P
Background
Our research group has previously established the cost-effectiveness (CE) of lung cancer screening (LCS) with low-dose computed tomography (LDCT) for both high-risk smokers and non-smokers in Hong Kong (HK). Integrating LCS into the existing infrastructure in HK however requires systematic and rigorous design and execution. Thus, we undertook sensitivity and scenario analyses for LCS beyond fundamental base-case examination. The aim was to explore balance between clinical efficacy and resource optimization for LCS implementation in HK.
Methods
A CE analysis was conducted using decision tree and state-transition Markov model to simulate identification, diagnosis, and treatments for a high-risk population defined by the NELSON study and the TALENT study. One-way sensitivity analysis (OSA) was conducted with ±20% variation of the base-case parameter values. Scenario analyses were undertaken to explore the CE of LCS with varying costs. The incremental cost-effectiveness (ICER) was estimated as costs per quality-adjusted life-year (QALY).
Results
OSA showed that LDCT costs were the main driver for the ICER of LCS targeting heavy smokers, 20% increase in LDCT costs led to an ICER of USD 18,002 (22% higher than base-case ICER). Meanwhile, 20% increase in the treatments costs for stage I LC led to an ICER of 10,844 (7% higher than base-case ICER) for the LCS targeting high-risk non-smokers. Scenario analyses additionally indicated that restraining costs for CT scan, diagnosis, and early-stage LC treatments would yield a reduction in ICER (Table). Table: 486P
Scenario analysis | Smoker | Non smokers | ||
ICER (USD) ∗ | Reduction in ICER ∗ | ICER (USD) | Reduction in ICER | |
Base-case analysis | $14,723 | NA. | $10,096 | NA. |
Cut down unit costs for low-dose CT scans (LDCT) - USD $ 191 | $12,070 | 18% | $9,520 | 6% |
Cut down unit costs for LDCT - USD $ 127 | $9,377 | 36% | $8,934 | 12% |
Cut down unit costs for LDCT - USD $ 64 | $6,684 | 55% | $8,349 | 17% |
Half diagnostic costs for stage I - USD $ 836 (per person) | $14,472 | 2% | $9,635 | 5% |
Half diagnostic costs for stage IV - USD $ 3,922 (per person) | $14,969 | -2% | $8,872 | 12% |
Half treatment costs for the ongoing phase for stage I patients (per 3 months) - USD $ 247 | $13,296 | 10% | $8,777 | 13% |
Half treatment costs for the ongoing phase for stage IV patients (per 3 months) - USD $ 417 | $14,974 | -2% | $10,145 | 0% |
Conclusions
Fiscal restraint on CT scanning and early-stage LC treatments expenditures are necessary to ensure feasible and sustainable LCS implementation in HK. Our findings provide important benchmarks for the HK Government’s consideration.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca Hong Kong.
Disclosure
H.H.F. Loong: Financial Interests, Institutional, Invited Speaker: Boehringer Ingelheim, MSD; Financial Interests, Personal, Invited Speaker: Eli Lilly, Illumina, Bayer, Guardant Health; Financial Interests, Personal, Advisory Board: Novartis, Takeda. X. Pan: Financial Interests, Personal, Financially compensated role: i-DNA. All other authors have declared no conflicts of interest.
Resources from the same session
372P - Effectiveness of HAN-MI-RADS (head and neck molecular imaging-reporting and data system) criterion in head and neck squamous cell carcinoma post concurrent chemoradiotherapy
Presenter: Manoj Gupta
Session: Poster Display
Resources:
Abstract
373P - Investigating the impact of treatment on geriatric patients with locally advanced head and neck squamous cell carcinoma
Presenter: Yen Ting Liu
Session: Poster Display
Resources:
Abstract
374P - Immunohistochemical evaluation of oral lichen planus: A prospective clinical study
Presenter: Saravanan Sampoornam Pape
Session: Poster Display
Resources:
Abstract
375P - Survival and prognostic factors of head and neck squamous cell carcinoma patients treated with either definitive CCRT or post operative CCRT with platinum-based chemotherapy in Rajavithi hospital, Thailand
Presenter: wanit samadee
Session: Poster Display
Resources:
Abstract
376P - Nutrition as an independent prognostic factor in locally advanced nasopharyngeal carcinoma: A retrospective cohort study and propensity score-matched analysis
Presenter: haizhen yi
Session: Poster Display
Resources:
Abstract
377P - Oropharyngeal squamous cell carcinomas in Indian population: P16 positivity and treatment outcomes following chemoradiotherapy
Presenter: Parth Verma
Session: Poster Display
Resources:
Abstract
378P - A real-world retrospective analysis of the efficacy of pembrolizumab combined with chemotherapy as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (LA HNSCC)
Presenter: zhu Liu
Session: Poster Display
Resources:
Abstract
379P - Nimotuzumab in combination with chemoradiation for patients with intermediate stage and locally advanced nasopharyngeal carcinoma: A retrospective comparative analysis using 5-year real-world survival data
Presenter: Andhika Rachman
Session: Poster Display
Resources:
Abstract
380P - An epidemiological analysis on the prevalence of oral cancer and its awareness among Irula tribes of South India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
381P - P16INK4 over-expression, early stages, keratinization, and surgical margin-free status are associated with better prognosis of oral squamous cell carcinoma (OSCC)
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract